Dyslipidaemia in diabetes – an approach to therapeutic intervention by Raal, FJ
SA Fam Pract 2006:48(10)42
Dyslipidaemia in diabetes – 
an approach to therapeutic intervention
Raal FJ, FCP (SA), FRCP, FRCPC, MMed (Wits), PhD
Professor and Head, Division of Endocrinology and Metabolism, Department of Medicine, Johannesburg Hospital
Correspondence to: Prof. FJ Raal, e-mail: Frederick.raal@wits.ac.za
Introduction
Diabetes mellitus is a metabolic and cardiovascular disease and although the diagnosis is confirmed on blood glucose 
levels and anti-diabetic treatment is usually aimed at reducing glucose levels, the major contributor to mortality is, in fact, 
cardiovascular disease and in particular, coronary artery disease. This article discusses the difference between the lipid 
profiles of type 1 and type 2 diabetes and gives practical guidelines for pharmacological and lifestyle interventions to reduce 
cardiovascular mortality and hospitalisations.
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Introduction
Macrovascular disease, or atherosclero-
sis, accounts for at least 70% of all mor-
tality in diabetic patients. About 75% of 
this atherosclerotic diabetic mortality is 
the consequence of coronary artery dis-
ease (CAD); the remaining 25% results 
from a combination of accelerated cere-
brovascular disease, peripheral vascu-
lar disease, or both. When compared to 
non-diabetics, men with diabetes have 
twice the incidence, and diabetic wom-
en four times the incidence, of CAD. In 
addition, the cardioprotection afforded 
to non-diabetic women as compared 
to men is lost in women with diabetes. 
Most hospitalisations for diabetic com-
plications are attributable to macrovas-
cular disease. Myocardial infarction and 
stroke are more extensive in diabetics 
and are likely to be more rapidly fatal 
than in non-diabetics. Finally, up to 50% 
of patients with type 2 diabetes have 
pre-existing CAD at the time of diabetes 
diagnosis.1 
Lipid disturbances are common in 
diabetic subjects, and probably con-
tribute to the high incidence of vascular 
disease in these patients. Dyslipidaemia 
should therefore be looked for, and 
treated, in every diabetic patient.
Lipid abnormalities in diabetes 
At least 50% of all diabetics, whether 
type 1 or type 2, are dyslipidaemic. 
Abnormalities in both triglyceride and 
cholesterol abnormalities can occur.2
Dyslipidaemia in type 1 diabetes
Poorly controlled type 1 patients often 
have elevated triglyceride and, to a 
lesser extent, cholesterol levels. How-
ever, in well-controlled patients, the 
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•  Atherosclerosis, or macrovascular disease, accounts for at least 70% of mortality in 
diabetic patients.
•  Optimum glycaemic control in diabetic patients can prevent or even reverse the micro-
vascular complications of diabetes. However, the treatment of hyperglycaemia per se 
has had little impact on morbidity and mortality from macrovascular disease in diabet-
ics.
•  Lipid disturbances are common in diabetics, and probably contribute to the high inci-
dence of vascular disease in these patients.
•  There is a poor correlation between the degree of glycaemic control and the severity of 
hyperlipidaemia.
•  The ideal lipid profile in a diabetic subject is total cholesterol < 4. 5 mmol/L and LDL 
cholesterol < 2.5 mmol/L. 
•  Statin therapy in diabetics can reduce the risk of recurrent coronary events and prolong 
life.
•  Optimum management of the diabetic patient involves more than just glucose control. 
Hypertension, dyslipidaemia and other risk factors for atherosclerosis must be looked 
for and aggressively treated in all diabetic patients.
levels of total cholesterol, triglyceride 
and LDL cholesterol are similar to those 
of age-matched non-diabetic individu-
als. In type 1 diabetes, the risk of CAD 
is mainly related to the duration of the 
disease and the presence of nephropa-
thy. Subjects who develop diabetic 
renal disease, both microalbuminuria 
and frank proteinuria, have higher blood 
pressures, higher total cholesterol, LDL 
cholesterol and triglyceride, and lower 
HDL cholesterol levels; that is, they ac-
quire the lipid profile which predisposes 
to atherosclerosis.3
Dyslipidaemia in type 2 diabetes
It is important to recognise that type 2 
diabetes is not solely a disorder of car-
bohydrate metabolism, but that lipid ab-
normalities are equally prevalent. Type 
2 diabetes can be considered one com-
ponent of the metabolic or ‘insulin resis-
tant’ syndrome – a cluster of metabolic 
disorders including impaired glucose 
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 Hyperinsulinaemia
 Impaired glucose tolerance   →    
 type 2 diabetes mellitus
 Hypertension




 Small dense LDL




 Polycystic Ovarian syndrome   
 (PCOS)
 Non-alcoholic fatty liver disease   
 (NAFLD)
 Sleep apnoea syndrome
 Elevated inflammatory markers   
 (sCRP)
  Reduced adiponectin level
Table I: The metabolic or ‘insulin resistant’ 
syndrome
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tolerance, hypertension, abdominal 
obesity and dyslipidaemia, which is as-
sociated with a high prevalence of CAD 
(see Table I).4 
There are two main types of lipid ab-
normalities in type 2 diabetes:
Changes in the absolute concentra-
tions of lipids and lipoproteins
The most frequently encountered distur-
bances in circulating lipids and lipopro-
teins in type 2 diabetes are an increase 
in serum triglyceride concentrations and 
a reduction in HDL cholesterol (usually 
by 15 to 25%). These changes tend to 
be more striking in women than in men. 
The hypertriglyceridaemia is due to an 
overproduction of triglyceride-rich lipo-
proteins (VLDL) by the liver, as well as to 
decreased removal of triglyceride-rich 
particles from the circulation because 
of decreased lipoprotein lipase activity. 
There are no consistent changes in LDL 
cholesterol, but levels tend to be mildly 
elevated. Elevated triglyceride levels 
and low HDL cholesterol levels are also 
seen in the metabolic syndrome prior to 
the onset of overt diabetes, and this may 
explain why CAD is often present at the 
time of diagnosis of type 2 diabetes.1
Changes in the composition of lipids 
and lipoproteins
LDL particles tend to be smaller and 
denser in type 2 diabetes and this may 
increase their atherogenicity. These 
small, dense particles can penetrate the 
arterial wall more readily and bind more 
avidly to proteoglycans, which results in 
them being trapped within the arterial 
wall. In addition, chemical modification 
of lipoproteins, by glycation or oxida-
tion, both of which are increased, may 
induce endothelial injury and accelerate 
foam cell formation by macrophages 
within the arterial wall.
Why treat the lipid abnormalities in 
diabetes?
• Diabetes mellitus is a cardiovascular 
disease, and coronary artery dis-
ease is the major cause of death in 
diabetics.
• The cardioprotective effect is lost in 
women with diabetes.
• Treatment of hyperglycaemia per se 
has had little impact on the morbid-
ity and mortality from macrovascular 
disease in diabetes.
Therapy for diabetic dyslipidaemia
The therapy for diabetic dyslipidaemia 
consists of diet, weight loss and 
exercise, optimisation of glycaemic 
control and, where appropriate, lipid-
lowering therapy.
• Diet, weight loss and exercise
An inappropriate diet is the major con-
tributor to dyslipidaemia in diabetes, 
particularly type 2 diabetes. The corner-
stone of therapy for diabetic dyslipidae-
mia is therefore an appropriate diet (see 
Table II). The majority of type 2 patients 
are overweight or frankly obese. Weight 
loss, even if modest, is of great value in 
improving the dyslipidaemia, as well as 
diabetic control, in these patients, but 
is unfortunately difficult to achieve in 
practice.
  (% of calories)
Total fat  < 30%
saturated fat < 10%
monounsaturated 10-15%
polyunsaturated up to 10%
Carbohydrate 50-60%
Protein  10-20%
Cholesterol < 300 mg/day
Table II: Recommended diabetic diet
• Diabetic control
Poor metabolic control is a contributor 
to diabetic dyslipidaemia. It therefore 
is important to ensure that the diabe-
tes is under adequate control with oral 
hypoglycaemic agents and/or insulin. 
This should be assessed by fasting/
postprandial glucose levels, as well as 
by the measurement of glycated hae-
moglobin.
In type 1 diabetic patients, the 
Diabetes Control and Complications 
(DCCT) trial has clearly established that 
optimum glycaemic control can prevent 
or even reverse the microvascular com-
plications of diabetes and may delay the 
onset of macrovascular disease.5 
In type 2 diabetes it is important to note 
that:
a) Epidemiological studies have failed 
to show a relationship between 
indices of glycaemic control and 
the prevalence of macrovascular 
disease.
b) There is a poor correlation between 
glycaemic control and the degree of 
hyperlipidaemia.
c) Sulphonylureas and biguanides, as 
well as the glitazones, have only 
limited effects on serum lipids and 
lipoproteins. These drugs do not sig-
nificantly lower serum cholesterol, 
triglycerides or affect HDL choles-
terol, despite improved glycaemic 
control. This could be the reason 
that we have seen little decrease in 
cardiovascular mortality whilst oral 
hypoglycaemic agents have been 
the mainstay of treatment of type 2 
diabetes.
d) Most importantly, studies to date 
have shown that the treatment of 
hyperglycaemia per se has had little 
impact on the morbidity and/or mor-
tality from macrovascular disease in 
type 2 diabetes. The United King-
dom Prospective Diabetes Study 
(UKPDS) has shown a decrease 
in cardiovascular mortality with im-
proved glycaemic control, but this 
decrease was modest at best.6 
 
In summary, a good diet, weight loss 
and improved glycaemic control will 
improve, but not always correct, the 
lipid disorder, and may therefore not in-
fluence the most important complication 
in diabetic patients, namely atheroscle-
rosis. It is also important to remember 
that diabetic patients are frequently 
hypertensive and that certain antihyper-
tensives, particularly thiazide diuretics 
and ß-blockers, can aggravate lipid 
disturbances in diabetic subjects.
Therefore, provided that secondary 
causes for hyperlipidaemia, such as 
alcohol excess, drug therapy and hy-
pothyroidism, have been excluded, 
lipid-lowering therapy should be consid-
ered in all diabetics who fail to respond 
adequately to dietary therapy.
• Lipid-lowering drug therapy
If routine antidiabetic strategies, in-
cluding diet, weight loss and improved 
glycaemic control, do not successfully 
normalise lipid levels within three to six 
months, lipid-lowering drug therapy 
should be instituted. In the UKPDS, LDL 
cholesterol was found to be the most im-
portant independent risk factor for CAD 
(see Table III).7 In addition, the American 
Diabetes Association and the European 
Atherosclerosis Society have recently 
recommended that diabetes mellitus 
be considered a CAD equivalent and 
that lipid goals in diabetics should be 
the same as in patients with established 
CAD (see Table IV).8 There is also 
a strong argument for immediately 
instituting lipid-lowering drug therapy 
in all diabetics with established CAD, 
regardless of the LDL cholesterol level.9 
Table III: Ideal fasting lipid profile in a dia-
betic patient
Total cholesterol < 4.5 mmol/L 
LDL-cholesterol  < 2.5 mmol/L
Triglycerides < 1.7 mmol/L 
HDL cholesterol > 1 mmol/L (male)
  > 1.2 mmol/L (female)
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Several lipid-lowering drugs are cur-
rently available for the treatment of 
hyperlipidaemia. Bile acid sequestrants 
should be avoided in the management 
of diabetic dyslipidaemia, as they can 
provoke an increase in serum triglyc-
erides and lower HDL cholesterol levels 
further in diabetic patients. Nicotinic 
acid should also be avoided, as it may 
worsen glycaemic control. The most 
useful drugs for the management of 
diabetic dyslipidaemia are the statins 
and the fibrates.
The HMG-CoA reductase inhibitors 
or statins
The statins are powerful cholesterol-low-
ering agents and have revolutionised 
the management of hyperlipidaemia. 
These drugs consistently lower serum 
total  and LDL cholesterol by 15 to 65% 
without interfering with diabetic control. 
Statins are mainly used for the therapy 
of hypercholesterolaemia rather than 
combined hyperlipidaemia, as is pres-
ent in the majority of diabetic patients. 
However, recent subgroup analyses of 
large landmark secondary prevention 
trials, such as the 4S, CARE, LIPID and 
HPS studies, have shown that effec-
tive reduction of serum total  and LDL 
cholesterol levels in type 2 patients with 
established CAD results in a marked re-
duction in the risk of recurrent coronary 
events (see Table V).10
More recently, the CARDS study 
confirmed these findings. CARDS was 
a double-blind, placebo-controlled clini-
cal trail of atorvastatin 10 mg daily ver-
sus placebo in 2 838 patients with type 
2 diabetes with risk factors for cardio-
vascular disease, but with no previous 
history of heart disease or stroke. After 
a follow-up of four years, treatment with 
atorvastatin 10 mg/day was associated 
with a highly significant 37% reduction 
in the incidence of the primary end point 
of major coronary events and stroke 
(p=0.001). All-cause mortality was re-
duced by 27% (p=0.059) and stroke 
by 48% (p=0.016). Overall, the CARDS 
investigators considered that the results 
strengthened the evidence for more 
widespread use of statin therapy in dia-
betics, and that lipids should receive at 
least as much attention as glucose and 
blood pressure, even if LDL cholesterol 
is not markedly elevated.11
Fibric acid derivatives
The fibrates decrease serum triglycer-
ides by 30 to 50%, serum cholesterol 
by 10 to 15%, and elevate serum HDL 
cholesterol by 10 to 15%. All of these 
Table IV: Independent risk factors for coronary artery disease in the United Kingdom Prospec-
tive Diabetes Study (UKPDS)7
Risk factor Upper third
cut-off point
Hazard ratio
Dyslipidaemia LDL > 3.9 mmol/L 2.26
Hypertension SBP > 142 mm Hg 1.82
Hyperglycaemia HBA1 > 7.5 % 1.52
Cigarette smoking current 1.41













4S (N = 4444) 202 32% 55% 29% 43%
CARE  (N = 4159) 586 23% 25% - -
LIPID (N = 9014) 782 25%  19% - -
HPS (N = 20536)  5963 27% 27% 24% 22% *
CARDS (N = 2838) 2838 - 37% - 27%
ASCOT- LLA 2532 36% 17% - -
4S = The Scandinavian Simvastatin Survival Study
CARE = The Cholesterol and Recurrent Events Study 
LIPID = The Long-Term Intervention with Pravastatin in Ischaemic Disease Study
HPS = The Heart Protection Study
CARDS = The Collaborative Atorvastatin Diabetes Study
ASCOT-LLA = The Anglo Scandinavian Cardiac Outcomes Study (Lipid-lowering arm)
are beneficial in patients with diabetes. 
In addition, LDL particle size is shifted 
towards larger, less dense particles and 
postprandial lipoprotein clearance is en-
hanced. In some studies, treatment with 
fibrates has also been shown to improve 
glycaemic tolerance in type 2 diabetes. 
Unfortunately, in spite of the favourable 
alterations by fibrates, studies such as 
the Veterans Affairs High Density Li-
poprotein Cholesterol Intervention Trial 
(VA-HIT) and Bezafibrate Infarction Pre-
vention Study (BIP), have only shown 
only a modest reduction in cardiovascu-
lar morbidity. A more recent study, the 
FIELD study, the largest fibrate study 
to date – involving 9 795 subjects with 
type 2 diabetes who were randomised 
to fenofibrate or placebo – showed only 
a disappointing 11% reduction in the 
primary end point of coronary events, 
which was not significant (p=0.16).12 
The results of the FIELD study therefore 
do not support the use of fibrates as first 
choice for patients with diabetic dyslipi-
daemia. 
Statin versus fibrate versus combina-
tion therapy?
The results of the statin trials in patients 
with diabetes provide more convincing 
evidence of cardiovascular benefit than 
the fibrate trials. I would therefore cur-
rently recommend statin therapy for all 
diabetic patients with predominant hy-
percholesterolaemia or mixed hyperlipi-
daemia with mild hypertriglyceridaemia. 
Fibrates should be restricted to those di-
abetic patients with moderate to severe 
hypertriglyceridaemia (triglyceride > 5 
mmol/l), provided the LDL cholesterol 
goal of 2.5 mmol/L is achieved with this 
medication. If the LDL cholesterol goal is 
not achieved with fibrate therapy alone, 
combination therapy with a statin with or 
without ezetimibe may be required. 
Conclusions
Preoccupation with the management of 
hyperglycaemia, however useful in pre-
venting microvascular complications of 
diabetes, has outweighed the diagnosis 
and management of other established 
risk factors for macrovascular disease, 
such as hypertension and dyslipidae-
mia.13 Diabetic dyslipidaemia, in par-
ticular, is often neglected and must be 
looked for and appropriately treated in 
all diabetic patients. Diabetes mellitus is 
more than just hyperglycaemia!. 
See CPD Questionnaire, page 48
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Refresher Course for 
General Practitioners 2007
Stellenbosch University, StellMed Updates 
will be presenting this course next year on 9, 
10 & 11 May 2007. The following topics will 
be covered:
Orthopaedics: Orthopaedic Emergen-
cies and Small Procedures eg. Aspiration 
of Joints and Intra-articular Injections and 
Examinations, Common Ankle Injuries and 
Mechanical Disorders of the Knee.
Urology: Urinary Stones, Prostate Cancer, 
Benign Prostate Hyperplasia (BPH), Prostati-
tis and Common Testicle Disorders.
Cardiology: Acute Coronary Syndromes 
(Angina, Chest Pain and Heart Failure), 
Common Arrhythmias, Modern Management 
of Heart Failure, an Approach to ECG Inter-
pretation and Recent Advances in Cardiac 
Imaging.
Neurology: An Update on Headaches, Mod-
ern Management of Stroke, Dementia and 
Alzheimer’s Disease, an Update on Epilepsy, 
Blackouts, Dizziness and Vertigo.
Paediatrics: Gastroentiritis and Pneumonia 
(The most common causes of mortalily in-
children), Paediatric Resuscitation Update, 
Poisoning in Children and Meningitis.
Ophtalmology: Basic Eye Examination, 
Common Eye Injuries, The Diabetic Eye, An 
Approach to Cataracts and The Red Eye.
A more detailed programme will be available 
in the beginning of 2007. Please reserve 
these dates in your diary to ensure that you 
do not miss this course.
Opknappingskursus vir 
Algemene Praktisyns 2007
Universiteit Stellenbosch, StellMed Updates 
sal hierdie kursus volgende jaar op 9, 10 & 
11 Mei 2007 aanbied. Die onderwerpe wat 
gedek gaan word is die volgende: 
Ortopedie: Ortopediese Noodgevalle en 
Kleiner Prosedures bv. Aspirasies van 
Gewrigte en Intra-artikulêre Inspuitings en 
Ondersoeke, Algemene Enkelbeserings en 
Kniebeserings.
Urologie: Nierstene, Aspekte van Prostaat-
kanker, Benigne Prostaathiperplasie, Prosta-
titis en Algemene Testikulêre Afwykings. 
Kardiologie: Akute Koronêre Sindrome (Bor-
skaspyn, Onstabiele Angina en Hartversak-
ing), Aritmië, Die Moderne Hantering van ‘n 
Hartaanval, Die Benadering tot Interpretasie 
van EKG’s en die jongste verwikkelinge in 
Kardiale Beelding. 
Neurologie: Benadering tot Hoofpyn, Han-
tering van Beroerte Aanvalle, Demensie en 
Alzheimer se siekte, Epilepsie, Floutes, Lig-
hoofdigheid en Vertigo.
Pediatrie: Gastroënterologie en Pneumonie 
(Die mees algemene oorsake van kinder-
sterftes), Pediatriese Resussitasie, Meningitis 
en Kindervergiftiging.
Oogheelkunde: Basiese Oogheelkundige 
Ondersoeke, Algemene Oogbeserings, Die 
Diabetiese Oog, ‘n Benadering tot Katarakte 
en die Rooi Oog.
‘n Meer volledige program sal vroeg in 2007 
beskikbaar wees. Hou asseblief solank 
hierdie datums in u dagboek oop om te 
verseker dat u dit nie misloop nie.
Vir meer inligting / For further information: 
www.stellmed.com 
